Repare Therapeutics Licenses Lunresertib to Debiopharm for Worldwide Development.

Repare Therapeutics has entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. Lunresertib has shown promising results across multiple clinical trials, and the agreement will enable continued development of the treatment. Repare is a clinical-stage precision oncology company with a focus on developing treatments for cancer.

Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A., a Swiss biopharmaceutical firm, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. The agreement, announced on July 15, 2025, will enable the continued development of lunresertib, which has shown promising results across multiple clinical trials targeting challenging solid tumors.

Under the terms of the agreement, Repare will receive an upfront payment of $10 million and is eligible to receive up to $257 million in potential clinical, regulatory, commercial, and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib.

Steve Forte, President, CEO, and CFO of Repare, stated, "The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat solid tumors. This agreement builds upon the success of Repare and Debiopharm’s existing collaboration studying the combination of lunresertib and Debio 0123."

Bertrand Ducrey, CEO of Debiopharm, expressed excitement about the partnership, stating, "Based on very promising Phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions. We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult-to-treat cancers."

Repare will continue to focus on its ongoing Phase 1 clinical trials, POLAR and LIONS. The POLAR clinical trial is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, a small molecule inhibitor of polymerase theta (Polθ) that is a synthetic lethality target associated with BRCA mutations and other genomic alterations. The LIONS clinical trial is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and the preliminary efficacy of RP-1664, a first-in-class, highly selective, oral inhibitor of Polo-like kinase 4 (PLK4) that is a synthetic lethality target associated with TRIM37 overexpression.

The agreement with Debiopharm supports Repare's mission to develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. This strategic move underscores the company's commitment to advancing its clinical pipeline and creating sustained value for investors and patients.

References:
[1] https://ir.reparerx.com/news-releases/news-release-details/repare-therapeutics-enters-exclusive-worldwide-licensing
[2] https://www.gurufocus.com/news/2979363/repare-therapeutics-rptx-secures-global-licensing-deal-with-debiopharm-rptx-stock-news